Design Principles for Maximizing the Drug Delivery Efficiency and Therapeutic Index of ADCs
|
|
- Stewart Summers
- 6 years ago
- Views:
Transcription
1 Design Principles for Maximizing the Drug Delivery Efficiency and Therapeutic Index of ADCs World ADC 217 San Diego Robert Lyon Sr. Director, Chemistry
2 Themes of the presentation This represents the desired fate of an ADC: What else can happen to ADC in plasma (step 1) that may prevent it from reaching step 2? How does that affect the therapeutic index? How can ADCs be designed to maximize the fraction that follows the desired path? 2 Confidential
3 Cysteine-based conjugation for Adcetris produces an average of 4 drugs / antibody 8 thiols per antibody Full reduction (excess TCEP) IgG1 Partial reduction (limiting TCEP) Conjugation with maleimido-drug linker thiols per antibody 8 drugs per antibody drugs per antibody (8) Why not use uniform ADCs with 8 drugs? Hydrophobic Interaction Chromatography () (2) (4) (6) (8) min time (min) W2996 Extraction at 28 nm min time (min) W2996 Extraction at 28 nm 3 Confidential
4 c on centration ( mg/ ml) High drug loading can result in faster clearance Conjugation with mc-vc-mmae: Antibody / ADC Pharmacokinetics 1 mc-vc-mmae loading reduced disulfide time (days) 8 4 reduced disulfides 4 Confidential Hamblett,K et al., Clinical Cancer Res. 24, 1,
5 [A b ] (m g /m l) Accelerated clearance of an ADC may be due to greater non-specific uptake Detection of hepatic uptake by IHC: 1 antibody 1 1 hepatic endothelium macrophages a n tib o d y A D C tim e (d a y s ) ADC 5 Confidential
6 [A b ] (m g /m l) Plasma clearance correlates with the apparent hydrophobicity of the ADC Auristatin ADCs with 8 drugs per antibody evaluated for apparent hydrophobicity and pharmacokinetics Hydrophobicity Mouse Pharmacokinetics (antibody concentration in plasma) 1 ADC: 28 nm HIC ADC 1 native h1f6 Auristatin T 1 mcmmaf mc-vc-mmaf min retention time (minutes) W2996 Extraction at 28 nm h1f6; ; 3/13/212 7:13:4 PM PDT W2996 Extraction at 28 nm h1f6-1251; ; 3/13/212 7:52:57 PM PDT W2996 Extraction at 28 nm h1f6-488; ; 3/13/212 8:12:54 PM PDT W2996 Extraction at 28 nm h1f6-1269; ; 3/13/212 8:32:51 PM PDT tim e (d a y s ) Hydrophobic Interaction Chromatography retention time predicts pharmacokinetics reasonably well 6 Confidential Lyon, R. P. et al. Nature Biotechnology 33, (215).
7 Can we mask the hydrophobic drug-linker component of an ADC? Hydrophobic patch introduced by drug conjugation in the IgG hinge Hydrophobicity masked by PEG PEG PEG is a hydrophilic polymer Low toxicity We can vary the length of the chain to tune the effect 7 Confidential
8 T o ta l A n tib o d y (m g /m l) Effect of PEG on ADC pharmacokinetics Glucuronide-MMAE drug-linker chosen for proof-of-concept 1 Glucuronide release trigger MMAE tim e (d a y s ) u n c o n ju g a te d DPR maleimide (imparts stability) A D C w ith o u t P E G 8 Confidential
9 T o ta l A n tib o d y (m g /m l) Effect of PEG on ADC pharmacokinetics Introduction of PEG 24 restores pharmacokinetics of parental antibody 1 Glucuronide release trigger MMAE tim e (d a y s ) u n c o n ju g a te d A D C w ith o u t P E G A D C w ith 2 4 P E G u n its DPR maleimide (imparts stability) PEG 24 9 Confidential
10 T o ta l A n tib o d y (m g /m l) Effect of PEG on ADC pharmacokinetics Introduction of PEG 24 restores pharmacokinetics of parental antibody Detection of hepatic uptake by IHC: tim e (d a y s ) u n c o n ju g a te d A D C w ith o u t P E G A D C w ith 2 4 P E G u n its 1 Confidential
11 T o ta l A n tib o d y (m g /m l) Effect of PEG on ADC pharmacokinetics Continuum of PEG length produces continuum of ADC clearance rates tim e (d a y s ) continuum of PEG lengths produces continuum of ADC clearance rates u n c o n ju g a te d P E G y la te d A D C s A D C w ith o u t P E G 2 # 4 o f 8 P E G 1 2 u n its Confidential
12 T o ta l A n tib o d y (m g /m l) C le a ra n c e (m L k g - 1 d ay - 1 ) Effect of PEG on ADC pharmacokinetics A D C c le a r a n c e a s a fu n c tio n o f P E G s iz e tim e (d a y s ) P E G y la te d A D C s P E G le n g th A D C w ith o u t P E G # o f P E G u n its These ADCs provide a set of tools to study the role of clearance rate on ADC pharmacology / toxicology 12 Confidential
13 T o ta l A n tib o d y (m g /m l) P e rc e n t S u rv iv a l* Clearance correlates with acute toxicity Faster clearance leads to greater toxicity Survival following 2 mg/kg dose tim e (d a y s ) P E G y la te d A D C s A D C w ith o u t P E G # 4 o f 8 P E G 1 2 u n its D a y s * e x c lu d in g p la n n e d s a c r ific e s a t S D 8 a n d S D 2 9 (All ADCs tolerated at 1 mg/kg dose) 13 Confidential
14 n g M M A E /g tis s u e Why are faster clearing ADCs more toxic? MMAE concentrations following 3 mg/kg dose of ADC L iv e r 3 S p le e n d a y s ADC catabolism Fast ADC catabolism d a y s Fast conversion of conjugated drug to free drug 14 Confidential
15 n g M M A E /g tis s u e n g M M A E /m L o f p la s m a Why are faster clearing ADCs more toxic? MMAE concentrations following 3 mg/kg dose of ADC 1 5 B o n e M a r r o w.3 P la s m a d a y s ADC catabolism Fast ADC catabolism d a y s Fast conversion of conjugated drug to free drug 15 Confidential
16 Histopathology reveals continuum of bone marrow depletion Rat bone marrow (sternum) 1 week post-dose 2 mg/kg untreated (4 days post-dose) 16 Confidential
17 P la te le t C o u n t (1 3 /m L ) N e u tro p h il C o u n t (p e r m L ) A b s R e tic u lo c y te (1 3 /m L ) A b s. E o s in p h il (p e r m L ) Hematology reflects bone marrow effects 6 R e tic u lo c y te s 1 mg/kg E o s in o p h ils S tu d y D a y 1 P la te le ts untreated S tu d y D a y N e u tr o p h ils mg/kg S tu d y D a y S tu d y D a y 17 Confidential
18 A L P (U /L ) A S T (U /L ) A L T (U /L ) Serum chemistry toxicity markers also follow the clearance continuum Mild elevations 1 week after a 1 mg/kg dose 4 A lk a lin e P h o s p h a ta s e 3 A s p a rta te A m in o tra n s fe ra s e 1 A la n in e A m in o tra n s fe ra s e Confidential
19 C o n c e n tr a tio n (n g /m L ) C o n c e n tr a tio n (n g /m L ) In murine xenograft models, greater plasma exposure drives sustained tumor uptake Radiolabeled anti-cd3 ADCs dosed at 1 mg/kg in L54cy model of Hodgkin lymphoma 1 Plasma pharmacokinetics 1 Tumor uptake T im e (d a y s ) T im e (d a y s ) Magnitude of pharmacokinetic differences are smaller in mice than in rats 19 Confidential
20 m e a n tu m o r v o lu m e (m m 3 ) re m a in in g m ic e Clearance correlates well with activity Slower clearance leads to greater antitumor activity Anti-CD19 ADCs dosed at 3 mg/kg in RL model of DLBCL d a y s p o s t im p la n t untreated d a y s p o s t tu m o r im p la n t 4 mice sacrificed when tumors reach 1 mm 3 2 Confidential
21 % d r u g r e m a in in g Understanding the relative impact of stability and clearance Four ADCs to interrogate plasma stability and non-specific uptake ADC incubation in plasma d a y s p o s t d o s e mc-val-cit- MMAE mdpr-val-cit- MMAE mc-(peg)- glucuronide- MMAE mdpr-(peg)- glucuronide- MMAE 21 Confidential
22 ] n M [M M A E ] n M [M M A E ] n M [M M A E ] n M [M M A E ] n M Free MMAE tissue profiles from DAR 8 ADCs MMAE C max in tissues dominated by fast ADC clearance, not drug-linker stability mc linkers (prone to maleimide loss) Δc max <2 fold mdpr linkers (completely stable) Val-Cit linkers b o n e m a rr o w 5 liv e r s p le e n 5 ly m p h n o d e (ADCs clear quickly) liv e r s p le e n s p le e n ly m p h 1 5n o d e ly 2 m4p h 6n o d8 e Δc max 2 8 fold ly m p h n o d e 1 1 PEGylated Glucuronide linkers (ADCs clear slowly) 5 22 Confidential T im e (d a y s ) T im e (d a y s )
23 Percent CD48+ Plasma Cells New MMAE drug-linker applied to a new antigen: SGN-CD48A Anticipated IND in Q4 of 217 CD48: A validated multiple myeloma antigen 9% of MM patients 26% of examined MM patients were previously treated or relapsed MM Patient Number 23 Confidential
24 S u rv iv in g M ic e (% ) S u rv iv in g M ic e (% ) S u rv iv in g M ic e (% ) S u rv iv in g M ic e (% ) Preclinical activity models of SGN-CD48A E J M - 7 S tu d y (D a y -1 3 ) E J M - 7 S tu d y (D a y -1 3 ) 8 6 U n tre a te d D a y s P o s t T u m o r Im p la n t N C IH s tu d y (D a y -1 2 F IN A L ) D a y s P o s t T u m o r Im p la n t 8 U n tre a te d 6 h ( 8 ) [M D P R - P E G g lu c -M M A E ] 1 m g /k g UUntreated n a te d Non-binding ADC 1. mg/kg h (8 ) [M D P R -P E G 1 2 -g lu c -M M A E ] 1 m g /k g 4 h M E M (8 ) m g /k g h M E M (8 ) 1 m g /k g E J M - 7 S tu d y (D a y -1 3 ) Curative activity at 1 mg/kg in multiple disseminated models of MM EJM h M E M ( 8 ) [M D P R -P E G g lu c -M M A E ] m g /k g SGN-CD48A SGN-CD48A.33 mg/kg 1. mg/kg h (8 ) [M D P R -P E G 1 2 -g lu c -M M Ah E M] E1 Mm -1g /k 2g (8 ) 1 m g /k g h M E M (8 ) m g /k g 2 h M E M (8 ) 1 m g /k g D a y s P o s t T u m o r Im p la n t U n tre a te d h (8 ) [M D P R -P E G 1 2 -g lu c -M M A E ] 1 h M E M (8 ) m g /k g 4 h M E M (8 ) [M D P R -P E G g lu c -M M A E ] 1 m g /k g 2 NCI-H D a y s P o s t T u m o r Im p la n t MM.1R-luciferase 24 Confidential
25 Lessons from this work Higher released drug C max in tissues Increased toxicity Excessive ADC hydrophobicity Non-specific ADC interactions Faster ADC clearance in tissues Lower tumor exposure to ADC Decreased activity 25 Confidential
26 Lessons from this work Hydrophilic Excessive linkers ADC and hydrophobicity PEG masking Non-specific Highly ADC specific ADCs interactions Slow nonantigen Faster ADC clearance mediated in tissues clearance Higher Minimize released drug drug C C max in max in tissues tissues Maximize Lower tumor tumor exposure to exposure to ADC ADC Decreased Increased toxicity Decreased Increased activity 26 Confidential
27 Acknowledgments Scott Jeffrey Svetlana Doronina Tim Bovee Patrick Burke Translational Research Jessica Simmons, Haley Neff-LaFord, Cisco Zapata, Paul Pittman, Marti Anderson, Mechthild Jonas, Nagendra Chemuturi, Tim Lewis, Devra Olson Chemistry Joe Hamilton, Josh Hunter, Julia Cochran 27 Confidential Process Chemistry Minh Nguyen, Yunyu Mao, Malcolm Reider, Victoria Singletary, Wendel Doubleday Jonathan Drachman, Peter Senter, Dennis Benjamin
28 28 Partner with the Leader in ADCs Seattle Genetics is the global leader in ADC technology from bench to market o o o One of only 4 companies with a globally approved and marketed ADC: ADCETRIS (brentuximab vedotin) ~4% of current clinical stage ADCs utilize our technology ADC expertise remains central to our current and future business strategy Continually investing in broadening our extensive ADC platform o Antibodies, Payloads, Conjugation technologies Business development focused in 3 key areas: o Target-exclusive licensing of our diverse ADC platform for some level of strategic rights o In-licensing technologies that build on our ADC platform o In-licensing diverse research, pre-clinical & early clinical oncology programs (ADC / non-adc) Please contact our team via Roland Gendron o rgendron@seagen.com 28 Confidential
Control Strategies for Small Molecule Components of Antibody-Drug Conjugates
Control Strategies for Small Molecule Components of Antibody-Drug Conjugates Nathan C. Ihle, PhD Executive Director, Process Chemistry Seattle Genetics, Inc WCBP 2012 Antibody-Drug Conjugates: Balancing
More informationValidation of the GastroPlus TM Software Tool and Applications
Validation of the GastroPlus TM Software Tool and Applications Fagen Zhang and Leah Luna The Dow Chemical Company FZ/MB 01.11.11 Acknowledgements Michael Bartels Barun Bhhatarai (Novartis) Tyler Auernhammer
More informationSrdan Verstovsek, MD, PhD Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center
Efficacy and Safety of Pegylated Interferon Alpha- 2a in Patients with Essential Thrombocythemia (ET) and Polycythemia vera (PV): Results after a Median 7-year Follow-up of a Phase 2 Study Srdan Verstovsek,
More informationSTEEL PIPE NIPPLE BLACK AND GALVANIZED
Price Sheet Effective August 09, 2018 Supersedes CWN-218 A Member of The Phoenix Forge Group CapProducts LTD. Phone: 519-482-5000 Fax: 519-482-7728 Toll Free: 800-265-5586 www.capproducts.com www.capitolcamco.com
More informationBis sulfone Reagents. Figure 1.
Bis sulfone Reagents An intact IgG molecule has four accessible inter chain disulfide bonds that can be reduced to form eight free cysteine thiols, which can serve as sites for conjugation. The reaction
More informationInfluence of Bacterial Growth Rate on Dose Optimization of Linezolid for Treatment of Tuberculosis
Influence of Bacterial Growth Rate on Dose Optimization of Linezolid for Treatment of Tuberculosis Kristina Bigelow Johns Hopkins University School of Medicine 1/15/217 Linezolid Recently added to WHOs
More informationgender mains treaming in Polis h practice
gender mains treaming in Polis h practice B E R L IN, 1 9-2 1 T H A P R IL, 2 O O 7 Gender mains treaming at national level Parliament 25 % of women in S ejm (Lower Chamber) 16 % of women in S enat (Upper
More informationAlita Miller, PhD. Head of BioScience. April 24, 2017 ECCMID 2017 Vienna, Austria
ETX5 restoration of sulbactam activity against multidrug resistant Acinetobacter baumannii correlates with β-lactamase inhibition in vitro and in vivo Alita Miller, PhD Head of BioScience April, 07 ECCMID
More informationThe Bcl3 Story : Collabora2ve Drug Discovery In Ac2on
The Bcl3 Story : Collabora2ve Drug Discovery In Ac2on Dr Andrew Westwell Drug Development & Model Systems Package Lead Dr Luke Piggo> Research Associate, WCRC Rachel Savery Trials Project Manager (Early
More informationForm and content. Iowa Research Online. University of Iowa. Ann A Rahim Khan University of Iowa. Theses and Dissertations
University of Iowa Iowa Research Online Theses and Dissertations 1979 Form and content Ann A Rahim Khan University of Iowa Posted with permission of the author. This thesis is available at Iowa Research
More informationc. What is the average rate of change of f on the interval [, ]? Answer: d. What is a local minimum value of f? Answer: 5 e. On what interval(s) is f
Essential Skills Chapter f ( x + h) f ( x ). Simplifying the difference quotient Section. h f ( x + h) f ( x ) Example: For f ( x) = 4x 4 x, find and simplify completely. h Answer: 4 8x 4 h. Finding the
More informationM a n a g e m e n t o f H y d ra u lic F ra c tu rin g D a ta
M a n a g e m e n t o f H y d ra u lic F ra c tu rin g D a ta M a rc h 2 0 1 5, A n n a F ilip p o v a a n d J e re m y E a d e 1 W h a t is H y d ra u lic F ra c tu rin g? Im a g e : h ttp ://w w w.h
More informationInternal dose assessment of 177 Lu-DOTA-SP for quantification of arginine renal protection effect
Internal dose assessment of 177 Lu-DOTA-SP for quantification of arginine renal protection effect 1 Puerta N., 1 Rojo A., 2 Crudo J., 2 Zapata A., 2 Nevares N., 2 López Bularte A., 2 Perez J., 2 Zaretzky
More informationMeasuring Drug-to-Antibody Ratio (DAR) for Antibody-Drug Conjugates (ADCs) with UHPLC/Q-TOF
Measuring Drug-to-Antibody Ratio (DAR) for Antibody-Drug Conjugates (ADCs) with UHPLC/Q-TOF Application Note Biopharma Author Shuai Zuo Tao Bo Suresh Babu C.V. Agilent Technologies, Inc. Abstract In this
More informationA L A BA M A L A W R E V IE W
A L A BA M A L A W R E V IE W Volume 52 Fall 2000 Number 1 B E F O R E D I S A B I L I T Y C I V I L R I G HT S : C I V I L W A R P E N S I O N S A N D TH E P O L I T I C S O F D I S A B I L I T Y I N
More informationBET PROTACs Are More Broadly Effective Than BET Inhibitors. Dr. Kevin Coleman Arvinas, LLC New Haven, CT
BET PROTACs Are More Broadly Effective Than BET Inhibitors Dr. Kevin Coleman Arvinas, LLC New Haven, CT 1 Disclosures I am an employee of and have an equity stake in Arvinas 2 Arvinas: The Protein Degradation
More informationThis presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform
This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements
More informationCTP-656 Tablet Confirmed Superiority Of Pharmacokinetic Profile Relative To Kalydeco in Phase I Clinical Studies
Tablet Confirmed Superiority Of Pharmacokinetic Profile Relative To Kalydeco in Phase I Clinical Studies 39 th European Cystic Fibrosis Conference 8-11 June 2016, Basel, Switzerland 2014 Concert Pharmaceuticals,
More informationPHA 4123 First Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 4123 First Exam Fall 1998 On my honor, I have neither given nor received unauthorized aid in doing this assignment. TYPED KEY Name Question 1. / pts 2. /2 pts 3. / pts 4. / pts. / pts 6. /10 pts 7.
More informationEKOLOGIE EN SYSTEMATIEK. T h is p a p e r n o t to be c i t e d w ith o u t p r i o r r e f e r e n c e to th e a u th o r. PRIMARY PRODUCTIVITY.
EKOLOGIE EN SYSTEMATIEK Ç.I.P.S. MATHEMATICAL MODEL OF THE POLLUTION IN NORT H SEA. TECHNICAL REPORT 1971/O : B i o l. I T h is p a p e r n o t to be c i t e d w ith o u t p r i o r r e f e r e n c e to
More informationActivation of STING with Synthetic Cyclic Dinucleotides and Synergy with Checkpoint Inhibition
Activation of STING with Synthetic Cyclic Dinucleotides and Synergy with Checkpoint Inhibition Sarah McWhirter, PhD Director, STING Program Aduro Biotech ICI Boston 2017 Presentation 1 Disclosures Sarah
More informationLU N C H IN C LU D E D
Week 1 M o n d a y J a n u a ry 7 - C o lo u rs o f th e R a in b o w W e w ill b e k ic k in g o ff th e h o lid a y s w ith a d a y fu ll o f c o lo u r! J o in u s fo r a ra n g e o f a rt, s p o rt
More informationAGRICULTURE SYLLABUS
Agriculture Forms 1-4.qxp_Layout 1 26/10/2016 12:29 PM Page 1 ZIMBABWE MInISTRY OF PRIMARY AnD SECOnDARY EDUCATIOn AGRICULTURE SYLLABUS FORM 1-4 2015-2022 Curriculum Development and Technical Services,
More informationOrgan-on-a-chip: practical applications & challenges. Remko van Vught
Organ-on-a-chip: practical applications & challenges Remko van Vught 10-4-2018 A leap forward in physiological relevance The challenge of reductionism: Make things as simple as possible, but not simpler,
More informationClass Diagrams. CSC 440/540: Software Engineering Slide #1
Class Diagrams CSC 440/540: Software Engineering Slide # Topics. Design class diagrams (DCDs) 2. DCD development process 3. Associations and Attributes 4. Dependencies 5. Composition and Constraints 6.
More informationMOLINA HEALTHCARE, INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationPolyethylene Glycol (PEG), High Sensitive ELISA
K-ASSAY Polyethylene Glycol (PEG), High Sensitive ELISA For the high sensitive quantitative determination of PEG and PEGylated proteins in serum or plasma Cat. No. KT-657 For Research Use Only. 1 K-ASSAY
More informationPIERIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationIsotope Production for Nuclear Medicine
Isotope Production for Nuclear Medicine Eva Birnbaum Isotope Program Manager February 26 th, 2016 LA-UR-16-21119 Isotopes for Nuclear Medicine More than 20 million nuclear medicine procedures are performed
More informationHigh Sensitivity Polyethylene Glycol (PEG) ELISA Kit
High Sensitivity Polyethylene Glycol (PEG) ELISA Kit Cat. No.:DEIA6158 Pkg.Size:96T Intended use High Sensitivity Polyethylene Glycol (PEG) ELISA Kit is High Sensitivity ELISA for the Measurement of PEG
More informationPhoto. EPRI s Power System and Railroad Electromagnetic Compatibility Handbook
Photo EPRI s Power System and Railroad Electromagnetic Compatibility Handbook Brian Cramer Project Manager Transmission and Substations bcramer@epri.com 815/478-5344 Problem Periodic false activation of
More informationLung-residing myeloid-derived suppressors display dual functionality in murine. pulmonary tuberculosis
Lung-residing myeloid-derived suppressors display dual functionality in murine pulmonary tuberculosis Julia K. Knaul, Sabine Jörg, Dagmar Oberbeck-Mueller, Ellen Heinemann, Lisa Scheuermann, Volker Brinkmann,
More informationCharacterizing degradation kinetics and cellular mechanisms of PROTAC compounds. Kristin M. Riching, Ph.D. Protein Degradation Therapeutics 2018
Characterizing degradation kinetics and cellular mechanisms of PROTAC compounds Kristin M. Riching, Ph.D. Protein Degradation Therapeutics 28 Understanding the Dynamics and Mechanisms of Protein Degradation
More informationMODELING THE ABSORPTION, CIRCULATION, AND METABOLISM OF TIRAPAZAMINE
MODELING THE ABSORPTION, CIRCULATION, AND METABOLISM OF TIRAPAZAMINE Olivia Nguyen and Xiaoyu Shi Problem Statement: Tirapazamine (TPZ; 1,2,4-benzotriazin-3-amine 1,4-dioxide) is a hypoxia-activated prodrug
More informationMarker-guided Targeted Therapy, PAPRi and Immune Checkpoint Therapy
Marker-guided Targeted Therapy, PAPRi and Immune Checkpoint Therapy Plenary Lecture 4 April 6, 3018 Global Breast Cancer Conference 2018 Incheon, Korea Mien-Chie Hung, PhD 洪明奇 Vice President for Basic
More informationFor the quantitative measurement of PEGylated molecules in plasma, serum and cell culture media
ab138914 Polyethylene Glycol (PEG) ELISA Kit Instructions for Use For the quantitative measurement of PEGylated molecules in plasma, serum and cell culture media This product is for research use only and
More informationANNUAL MONITORING REPORT 2000
ANNUAL MONITORING REPORT 2000 NUCLEAR MANAGEMENT COMPANY, LLC POINT BEACH NUCLEAR PLANT January 1, 2000, through December 31, 2000 April 2001 TABLE OF CONTENTS Executive Summary 1 Part A: Effluent Monitoring
More information600 Billy Smith Road, Athens, VT
600 Billy Smith Road, Athens, VT Curtis Trousdale, Owner, Broker, Realtor Cell: 802-233-5589 curtis@preferredpropertiesvt.com 2004 Williston Road, South Burlington VT 05403 www.preferredpropertiesvt.com
More informationPhysics. Sunday, March 4, :30 a.m. 10:00 a.m.
Physics Sunday, March 4, 2018 9:30 a.m. 10:00 a.m. Social Q&A Use your phone, tablet, or laptop to Submit questions to speakers and moderators Answer interactive questions / audience response polls astro.org/refreshersocialqa
More informationCHAPTER 7 SUMMARY AND CONCLUSIONS. constitutes the objective of many a research project in the field of pharmaceutical
CHAPTER 7 SUMMARY AND CONCLUSIONS Taste masking and development of palatable dosage forms of bitter drugs constitutes the objective of many a research project in the field of pharmaceutical technology.
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 8-K. Farmer Bros. Co.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event
More informationHemolysis and Immune Activation. Karina Yazdanbakhsh, PhD Executive Director, Research Institute New York Blood Center
Hemolysis and Immune Activation Karina Yazdanbakhsh, PhD Executive Director, Research Institute New York Blood Center Hemolysis in Sickle Cell Disease (SCD) Hemolysis activates the underlying endothelium:
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C Form 8-K/A (Amendment No. 2)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A (Amendment No. 2) Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report
More informationMulticompartment Pharmacokinetic Models. Objectives. Multicompartment Models. 26 July Chapter 30 1
Multicompartment Pharmacokinetic Models Objectives To draw schemes and write differential equations for multicompartment models To recognize and use integrated equations to calculate dosage regimens To
More informationTHE BANK OF NEW YORK MELLON CORPORATION (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationTechnology Platform 2018
Technology Platform 2018 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform
More informationTTM TECHNOLOGIES, INC. (Exact Name of Registrant as Specified in Charter)
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 15, 2006
More informationTechnical Challenges in the Analysis of PEGylated Proteins by Capillary Electrophoresis
Technical Challenges in the Analysis of PEGylated Proteins by Capillary Electrophoresis Ying-Chen Chen Biologics Process & Product Development Hopewell, NJ Outline PEGylation background information CE-SDS
More informationNonlinear pharmacokinetics
5 Nonlinear pharmacokinetics 5 Introduction 33 5 Capacity-limited metabolism 35 53 Estimation of Michaelis Menten parameters(v max andk m ) 37 55 Time to reach a given fraction of steady state 56 Example:
More informationB ooks Expans ion on S ciencedirect: 2007:
B ooks Expans ion on S ciencedirect: 2007: 1 INFORUM, 22-24 May, Prague Piotr Golkiewicz Account Manager Elsevier B.V. Email: p.golkiewicz@elsevier.com Mobile: +48 695 30 60 17 2 Pres entation Overview
More informationVlaamse Overheid Departement Mobiliteit en Openbare Werken
Vlaamse Overheid Departement Mobiliteit en Openbare Werken Waterbouwkundig Laboratorium Langdurige metingen Deurganckdok: Opvolging en analyse aanslibbing Bestek 16EB/05/04 Colofon Ph o to c o ve r s h
More informationTECH DATA CORPORATION (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest
More informationFunctional pottery [slide]
Functional pottery [slide] by Frank Bevis Fabens A thesis submitted in partial fulfillment of the requirements for the degree of Master of Fine Arts Montana State University Copyright by Frank Bevis Fabens
More informationJefferies Gene Editing/Therapy Summit Matthew Kapusta, Interim Chief Executive Officer OCTOBER 11, 2016
Jefferies Gene Editing/Therapy Summit Matthew Kapusta, Interim Chief Executive Officer OCTOBER 11, 2016 This presentation contains forward-looking statements. All statements other than statements of historical
More informationIsothermal experiments characterize time-dependent aggregation and unfolding
1 Energy Isothermal experiments characterize time-dependent aggregation and unfolding Technical ote Introduction Kinetic measurements have, for decades, given protein scientists insight into the mechanisms
More informationQuantification of NS1 dengue biomarker in serum via optomagnetic nanocluster detection
Supplementary Information Quantification of NS1 dengue biomarker in serum via optomagnetic nanocluster detection Paula Antunes 1, Daniel Watterson 3, Mattias Parmvi 1, Robert Burger 1, Anja Boisen 1, Paul
More informationData sheet. UV-Tracer TM Biotin-Maleimide. For Labeling of Thiol-groups with UV-detectable Biotin CLK-B Description
Cat. No. CLK-B105-10 CLK-B105-100 Amount 10 mg 100 mg For in vitro use only! Quality guaranteed for 12 months Store at -20 C 1. Description UV-Tracer TM Biotin Maleimide for biotinylation reactions of
More informationMatrix-assisted laser desorption ionization/time of flight (MALDI/TOF) mass spectra were obtained on
MALDI-TOF Mass Spectroscopy Matrix-assisted laser desorption ionization/time of flight (MALDI/TOF) mass spectra were obtained on Ultraflextreme (Bruker Daltonics, Germany) mass spectrometer using sinapinic
More informationGrain Reserves, Volatility and the WTO
Grain Reserves, Volatility and the WTO Sophia Murphy Institute for Agriculture and Trade Policy www.iatp.org Is v o la tility a b a d th in g? De pe n d s o n w h e re yo u s it (pro d uc e r, tra d e
More informationLynsi Rahorst, MT(ASCP) IRL Staff Technologist II. Everything But the Kitchen Sink!
Lynsi Rahorst, MT(ASCP) IRL Staff Technologist II Everything But the Kitchen Sink! 49 year old African American male with sickle cell anemia Requests for units Hospital A 6/03/2009-2 E-, Jk(b-) units 6/08/2009-2
More informationKalexsyn Overview Kalexsyn, Inc Campus Drive Kalamazoo, MI Phone: (269) Fax: (269)
Kalexsyn verview 2017 Kalexsyn, Inc. 4502 Campus Drive Kalamazoo, MI 49008 Phone: (269) 488-8488 Fax: (269) 488-8490 info@kalexsyn.com What we are Experienced medicinal chemists Conception and synthesis
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationInhibition of the AAA-ATPase p97 with the first in class inhibitor CB-5083 as a novel approach to treat cancer
Inhibition of the AAA-ATPase p97 with the first in class inhibitor CB-5083 as a novel approach to treat cancer Daniel Anderson, PhD Cleave Biosciences 1 Disclosure Information: AACR Annual meeting 2015
More informationNANO 243/CENG 207 Course Use Only
L8. Drug Dispersion and Diffusion in Biological Systems (2) April 26, 2018 2. Diffusion in Water (3) Diffusion of small molecule in water drug molecules/solvents are identical to solvent Assume molecules
More informationInformatics Framework to Support Integrative
Informatics Framework to Support Integrative Science and Engineering in Nanotechnology Stacey Lynn Harper, Ph.D. Environmental and Molecular Toxicology Chemical, Biological and Environmental Engineering
More informationCase Study of Electronic Materials Packaging with Poor Metal Adhesion and the Process for Performing Root Cause Failure Analysis
Case Study of Electronic Materials Packaging with Poor Metal Adhesion and the Process for Performing Root Cause Failure Analysis Dr. E. A. Leone BACKGRUND ne trend in the electronic packaging industry
More informationAdvantages of Agilent AdvanceBio SEC Columns for Biopharmaceutical Analysis
Advantages of Agilent AdvanceBio SEC Columns for Biopharmaceutical Analysis Comparing Columns from Different Vendors to Improve Data Quality Technical Overview Introduction Size exclusion chromatography
More informationTargeted Covalent Inhibitors: A Risk-Benefit Perspective
Targeted Covalent Inhibitors: A Risk-Benefit Perspective 2014 AAPS Annual Meeting and Exposition San Diego, CA, November 4, 2014 Thomas A. Baillie School of Pharmacy University of Washington Seattle, WA
More informationIn my opinion this paper can become suitable for publication, provided below issues are adequately addressed.
Reviewers' comments: Reviewer #1 (Remarks to the Author): Wagner and colleagues describe an appealing approach to modulate the properties of a drug, this case warfarin, by means of click chemistry in vivo.
More informationSupplementary Figure 1. Fullerence has poor solubility in water while the C60S and LC60S nanoparticles can be stably dispersed in water.
Supplementary Figure 1. Fullerence has poor solubility in water while the C60S and LC60S nanoparticles can be stably dispersed in water. (a) A typical photograph of fullerence (C60), C60S nanoparticles,
More informationIn Situ Gelation-Induced Death of Cancer Cells Based on Proteinosomes
Supporting information for In Situ Gelation-Induced Death of Cancer Cells Based on Proteinosomes Yuting Zhou, Jianmin Song, Lei Wang*, Xuting Xue, Xiaoman Liu, Hui Xie*, and Xin Huang* MIIT Key Laboratory
More informationExternal Magnetic Field Enhanced Chemo-Photothermal Combination Tumor. Therapy via Iron Oxide Nanoparticles
Supporting information External Magnetic Field Enhanced Chemo-Photothermal Combination Tumor Therapy via Iron Oxide Nanoparticles Xiaomeng Guo, Wei Li, Lihua Luo, Zuhua Wang, Qingpo Li, Fenfen Kong, Hanbo
More informationPeptides as Radiopharmaceuticals: CMC Perspectives
s as Radiopharmaceuticals: CMC Perspectives Ravindra K. Kasliwal, Ph.D. Office of New Drug Products (ONDP) Office of Pharmaceutical Quality (OPQ) Center for Drug Evaluation and Research (CDER) Food and
More informationReactive e Metabolite Trapping
Reactive e Metabolite Trapping Sylvia Zhao, Ph.D. China R&D and Scientific Affairs June 22, 2013 2013 南京国际药代会议 0 Outline Role of bioactivation in drug toxicity Reactive metabolite trapping methods Application
More informationEvaluating Human Health Risks from Nanomaterials
Evaluating Human Health Risks from Nanomaterials September 7, 2006 John R. Bucher, Ph.D., Director Toxicology Operations, NTP/NIEHS National Institute of Environmental Health Sciences/National Institutes
More informationSoftware Architecture. CSC 440: Software Engineering Slide #1
Software Architecture CSC 440: Software Engineering Slide #1 Topics 1. What is software architecture? 2. Why do we need software architecture? 3. Architectural principles 4. UML package diagrams 5. Software
More informationLesson Ten. What role does energy play in chemical reactions? Grade 8. Science. 90 minutes ENGLISH LANGUAGE ARTS
Lesson Ten What role does energy play in chemical reactions? Science Asking Questions, Developing Models, Investigating, Analyzing Data and Obtaining, Evaluating, and Communicating Information ENGLISH
More informationContribution of different oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in murine models of TB
Contribution of different oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in murine models of TB Rokeya Tasneen 1, Fabrice Betoudji 1, Véronique Dartois, Tian Yang
More informationTo take the slides out of full screen mode and display the Acrobat Reader controls, simply hit the Esc key on your computer keyboard.
HTLA Antibodies: Identification and Management Strategies and Case Studies Wednesday, April 17, 2013 2:00 p.m. 3:30 p.m. (ET) / 6:00p.m.-7:30 p.m. (GMT) When this file is opened, Acrobat Reader will, by
More informationThe general concept of pharmacokinetics
The general concept of pharmacokinetics Hartmut Derendorf, PhD University of Florida Pharmacokinetics the time course of drug and metabolite concentrations in the body Pharmacokinetics helps to optimize
More informationLSU Historical Dissertations and Theses
Louisiana State University LSU Digital Commons LSU Historical Dissertations and Theses Graduate School 1976 Infestation of Root Nodules of Soybean by Larvae of the Bean Leaf Beetle, Cerotoma Trifurcata
More informationChemical Lysine Modification at a single site. 2018/12/20 M1 Murata
Chemical Lysine Modification at a single site 2018/12/20 M1 Murata 1 Contents Amino acid target for bioconjugation Chemical Lysine modification N-hydroxysuccinimide (NHS)-ester α, β-unsaturated sulfonamide
More informationDelivery. Delivery Processes. Delivery Processes: Distribution. Ultimate Toxicant
Delivery Ultimate Toxicant The chemical species that reacts with the endogenous target. Toxicity depends on the concentration (dose) of the ultimate toxicant at the target site Delivery Processes Absorption
More informationBioorthogonal Prodrug Activation Driven by a Strain Promoted 1,3 Dipolar Cycloaddition
Bioorthogonal Prodrug Activation Driven by a Strain Promoted 1,3 Dipolar Cycloaddition 1 Siddarth S. Matikonda, Douglas L. rsi, Verena Staudacher, Imogen A. Jenkins, Franziska Fiedler, Jiayi Chen and Allen
More informationMySQL 5.1. Past, Present and Future. Jan Kneschke MySQL AB
MySQL 5.1 Past, Present and Future Jan Kneschke MySQL AB Agenda Past S Q L T re e s m e e ts D y n a m ic S Q L P re s e n t E v e n ts P a rtitio n in g F u tu re V e rtic a l P a rtitio n in g About
More informationStimuli-responsive reagents enable rapid biomarker capture and separation
Stimuli-responsive reagents enable rapid biomarker capture and separation Barrett J. Nehilla, PhD Nexgenia, Inc nehilla@nexgeniacorp.com 1 Evolution of Immunoassay Supports Where are the magnetic nanoparticles?
More informationLateral Flow: Making Magnetic Particles A Viable And Easier To Use Replacement To Gold Nanoparticles.
AN2 LATERAL FLOW COUPLING KIT Lateral Flow: Making Magnetic Particles A Viable And Easier To Use Replacement To Gold Nanoparticles. Introduction While lateral flow immunoassays represent a quick, low cost,
More informationIn Situ Detection of Protein Complexes and Modifications by Chemical Ligation Proximity Assay. Supporting Information.
In itu Detection of Protein Complexes and Modifications by Chemical Ligation Proximity Assay Rui ong*, Esteban Roberts and Christopher Bieniarz Technology and Applied Research, Ventana Medical ystems,
More informationS ca le M o d e l o f th e S o la r Sy ste m
N a m e ' D a t e ' S ca le M o d e l o f th e S o la r Sy ste m 6.1 I n t r o d u c t i o n T h e S olar System is large, at least w hen com pared to distances we are fam iliar w ith on a day-to-day basis.
More informationCertificate Sound reduction of building elements
Certificate Sound reduction of building elements Test report 040311.Z01b * ) Applicant GLAVERBEL GROUP Chaussée de la Hulpe 166 B- 1170 Brussels Specimen Monolithic glazing Foundation EN 20140-3 : 1995-01
More informationRadiotracers for Early Diagnosis - ReSearching for a Better Life!
Radiotracers for Early Diagnosis - ReSearching for a Better Life! CONTACT INFORMATION: Horia Hulubei National Institute of Physics and Nuclear Engineering - IFIN- HH 30 Reactorului Street 077125 Bucharest-Magurele,
More informationEvidence for the Existence of Non-monotonic Dose-response: Does it or Doesn t it?
Evidence for the Existence of Non-monotonic Dose-response: Does it or Doesn t it? Scott M. Belcher, PhD University of Cincinnati Department of Pharmacology and Cell Biophysics Evidence for the Existence
More informationCapacitor Discharge called CD welding
TROUBLE SHOOTING OF STUD WELDING (EQUPMENT) We see several time, that the two main principles of Studwelding are mixed up therefor I will start to repeat short the welding methods. Capacitor Discharge
More informationHigh Capacity Double Pillar Fully Automatic Bandsaw. p h a r o s 2 8 0
High Capacity Double Pillar Fully Automatic Bandsaw p h a r o s 2 8 0 A high-quality product from German mechanical engineering pharos - a beacon amongst automatic bandsaws Klaeger has been a leading manufacturer
More information, VX2. Em p ir ica l Study of Chem oem boliza tion Com b ined w ith Extract of Fung i of Hua ier on Hepa tic Tum or of Rabb it VX2
407 VX2 g g, 3,,,,, ( TACE) VX2 VX2 2,MR I VX2 3, 12, : A, 0. 2 m l/kg ; B TACE, 0. 2 m l/kg + 0. 5 mg/kg ; C TACE +, TA2 CE B, 500 mg/kg, 2,, ; 1 3 ( P > 0. 05) 2, B, A C ( P < 0. 05) ; A C ( P > 0. 05)
More informationby the detector. However, the ion
Guidelines for Masss Cytometry Panel Design 1 Mass Cytometry combines the advantages of single cell high speed analysis common to conventional flow cytometry with the ability to resolve over 90 metal probes
More informationof 2-Phenoxyethanol in B6D2F1 Mice
Summary of Drinking Water Carcinogenicity Study of 2-Phenoxyethanol in B6D2F1 Mice June 2007 Japan Bioassay Research Center Japan Industrial Safety and Health Association PREFACE The tests were contracted
More informationAn extrapolation framework to specify requirements for drug development in children
An framework to specify requirements for drug development in children Martin Posch joint work with Gerald Hlavin Franz König Christoph Male Peter Bauer Medical University of Vienna Clinical Trials in Small
More informationSupporting information
Supporting information The L-rhamnose Antigen: a Promising Alternative to α-gal for Cancer Immunotherapies Wenlan Chen,, Li Gu,#, Wenpeng Zhang, Edwin Motari, Li Cai, Thomas J. Styslinger, and Peng George
More information1980 Annual Report / FEDERAL R ESER V E BA N K OF RICHMOND. Digitized for FRASER Federal Reserve Bank of St.
1980 Annual Report / FEDERAL R ESER V E BA N K OF RICHMOND IS S N 0164-0798 L IB R A R Y OK C O N G R E SS C A T A L O G C A R D N U M B E R : 16-72o4 Additional <
More information